<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35261">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02059720</url>
  </required_header>
  <id_info>
    <org_study_id>SZ3702</org_study_id>
    <secondary_id>ChiCTR-TRC-14004196</secondary_id>
    <nct_id>NCT02059720</nct_id>
  </id_info>
  <brief_title>Haplo-SCT vs ASCT With or Without Decitabine in AML CR1</brief_title>
  <official_title>Haplo-mismatch Donor Stem Cell Transplantation (SCT) Versus Autologous SCT Followed or Not by Maintenance Therapy, for Patients With Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Group for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, prospective, open-label clinical study, including a randomized controlled
      study in low or intermediate-risk group patients, and a cohort study of maintenance
      treatment with decitabine after ASCT.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Leukemia-Free Survival</measure>
    <time_frame>Five years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Defined as the survival duration starting at the day of graft infusion, terminating at the day of death, morphological relapse or the end of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Five years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Defined as the survival duration starting at the day of graft infusion, terminating at the day of death or the end of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative relapse incidence</measure>
    <time_frame>Five years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as the cumulative incidence of morphological relapse after the day of graft infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality</measure>
    <time_frame>Five years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Defined as the cumulative incidence of death without cause of disease recurrence, which include the cause of GVHD, infection, hemorrhage, organic function failure, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of engraftment</measure>
    <time_frame>180 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as the cumulative incidence of durable complete donor chimerism detected by STR-PCR.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Five years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Including incidence and severity of acute and chronic GVHD, activity of daily living, psychological status, recovery of professional activity, social adaption, etc.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>auto</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receive autologous SCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>haplo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receive haplo-SCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HSCT</intervention_name>
    <description>Patients randomly assigned in to either of  groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.</description>
    <arm_group_label>auto</arm_group_label>
    <arm_group_label>haplo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18y

          -  Diagnosed as AML (except acute promyelocytic leukemia M3) for the first time

          -  Minimal Residual Disease (MRD) test can be achieved (molecular biology first if
             applicatable, and/or cytogenetics and/or immunophenotyping)

          -  Presence of an available haplo-mismatch related donor

        Exclusion Criteria:

          -  Contra-indications of chemotherapy or  hematopoietic stem cell transplantation

          -  Presence of an available identical sibling donor or a 10/10 HLA loci-matched
             unrelated donor

          -  Participating in other clinical trials concerning the prophylaxis of disease
             recurrence after ASCT

          -  No effective contraception

          -  Pregnant or lactating females

          -  Other causes which are not suitable for the trial in investigator's consideration
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Depei Wu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Fisrt Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>February 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>allogeneic hematopoietic stem cell transplantation</keyword>
  <keyword>autologous hematopoietic stem cell transplantation</keyword>
  <keyword>maintenance treatment</keyword>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
